Concepedia

Steven D. Averbuch

SD

38

Publications

13K

Citations

25

H-Index

1980

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

National Institutes of Health

Memorial Sloan Kettering Cancer Center

National Cancer Institute

AstraZeneca (United States)

Steven D. Averbuch is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacology.

Top concepts

Publications per year

1980–2023

38

Publications

38

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology · 2003 · 2.9K citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA · 2003 · 2.5K citations

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giuseppe Giaccone, Roy S. Herbst, Christian Manegold et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 829 citations

Rows per page

1–5 of 38